MabGenesis key facts
as of Oct 2026- Operator of a biopharmaceutical company intended to develop therapeutic monoclonal antibody drugs for humans and animals.
- MabGenesis is valued at approximately $18.6M as of Oct 2026 (last reported valuation).
- It has raised $8.8M; the latest was Later Stage VC ($3.1M) in Dec 2024.
- Notable investors include SMBC Venture Capital, Beyond Next Ventures, Regional Economy Vitalization Corporation of Japan, REVIC Capital, Anniversaire Holdings — 9 tracked in total.
- Status: Privately Held (backing).
MabGenesis's last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·Watch MabGenesis: the Monday email on marks, rounds and moves
MabGenesis funding rounds
No funding rounds for MabGenesis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
MabGenesis valuation
MabGenesis's last reported valuation was $18.6 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
MabGenesis investors
9 investors are on record for MabGenesis, including SMBC Venture Capital, Beyond Next Ventures, Regional Economy Vitalization Corporation of Japan and REVIC Capital.
About MabGenesis
Operator of a biopharmaceutical company intended to develop therapeutic monoclonal antibody drugs for humans and animals. The company specializes in discovering fully human and canine/feline therapeutic antibodies for humans and animals that can be licensed to pharmaceutical companies, providing the healthcare and pharmaceutical industry with new drug development opportunities.
- Sector
- Healthcare
- HQ
- Yokohama, Japan
- Founded
- 2019
- Website
- mabgenesis.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.